EUVIMEDEUVIMED entdecken
Systematische ÜbersichtOpen Access · CC BY-NC 4.0

Rethinking Tuberculosis Morbidity Quantification: A Systematic Review and Critical Appraisal of TB Disability Weights in Cost-Effectiveness Analyses

Ewan M Tomeny iD, Thomas Hampton, Phuong Bich Tran, Laura Rosu, Mphatso D Phiri, Kathryn A Haigh, Jasper Nidoi, Tom Wingfield, Eve Worrall

PharmacoEconomics · 2024

DOI: 10.1007/s40273-024-01410-x ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift PharmacoEconomics, 2024. Verfasst von Ewan M Tomeny und 8 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Sciences Department, Liverpool School of Tropical Medicine, Liverpool, UK. ewan.tomeny@lstmed.ac.uk. Hauptthemen laut MEDLINE: Cost-Benefit Analysis, Tuberculosis, Disability-Adjusted Life Years. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 160 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: The disability-adjusted life year (DALY), a key metric for health resource allocation, encompasses morbidity through disability weights. Widely used in tuberculosis cost-effectiveness analysis (CEAs), DALYs play a significant role in informing intervention adopt/reject decisions. This study reviews the values and consistency of disability weights applied in tuberculosis-related CEAs. METHODS: We conducted a systematic review using the Tufts CEA database, updated to July 2023 with searches in Embase, Scopus and PubMed. Eligible studies needed to have included a cost-per-DALY ratio, and additionally either evaluated a tuberculosis (TB) intervention or included tuberculosis-related weights. We considered all tuberculosis health states: with/without human immunodeficiency virus (HIV) coinfection, TB treatments and treatment side effects. Data were screened and extracted independently by combinations of two authors. FINDINGS: A total of 105 studies spanning 2002-2023 across 50 countries (mainly low- and middle-income countries) were extracted. Disability weights were sourced primarily from the Global Burden of Disease (GBD; 100/165; 61%), with 17 non-GBD studies additionally referenced, along with primary derivation. Inconsistencies in the utilisation of weights were evident: of the 100 usages of GBD-sourced weights, only in 47 instances (47%) had the weight value been explicitly specified with an appropriate up-to-date reference cited (constituting 28% of all weight usages, 47/165). Sensitivity analyses on weight values had been conducted in 30% of studies (31/105). Twelve studies did not clearly specify weights or their sources; nine further calculated DALYs without morbidity. The review suggests methodological gaps in current approaches for representing important aspects of TB, including TB-HIV coinfection, treatment, drug-resistance, extrapulmonary TB and psychological impacts. We propose a set of best practice recommendations. INTERPRETATION: There is a need for increased rigour in the application, sensitivity testing and reporting of TB disability weights. Furthermore, there appears a desire among researchers to reflect elements of the tuberculosis experience beyond those allowed for by GBD disability weights.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cost-Benefit AnalysisTuberculosisDisability-Adjusted Life YearsHumansHIV InfectionsQuality-Adjusted Life YearsPersons with DisabilitiesGlobal Burden of DiseaseAntitubercular Agents

Substanzen

Antitubercular Agents

Autor:innen und Institutionen

  • Clinical Sciences Department, Liverpool School of Tropical Medicine, Liverpool, UK. ewan.tomeny@lstmed.ac.uk.
  • Clinical Sciences Department, Liverpool School of Tropical Medicine, Liverpool, UK.
  • Institute of Life Course and Medical Sciences, University of Liverpool, Liverpool, UK.
  • Malawi Liverpool Wellcome Trust Clinical Research Programme, Blantyre, Malawi.
  • Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK.
  • Institute of Infection, Veterinary and Ecological Sciences, University of Liverpool, Liverpool, UK.

ORCID-Profile: Ewan M Tomeny

Zitieren

APA

Tomeny, E. M., Hampton, T., Tran, P. B., Rosu, L., Phiri, M. D., Haigh, K. A., Nidoi, J., Wingfield, T., & Worrall, E. (2024). Rethinking Tuberculosis Morbidity Quantification: A Systematic Review and Critical Appraisal of TB Disability Weights in Cost-Effectiveness Analyses. PharmacoEconomics. https://doi.org/10.1007/s40273-024-01410-x

Vancouver

Tomeny EM, Hampton T, Tran PB, Rosu L, Phiri MD, Haigh KA, et al. Rethinking Tuberculosis Morbidity Quantification: A Systematic Review and Critical Appraisal of TB Disability Weights in Cost-Effectiveness Analyses. PharmacoEconomics. 2024. doi:10.1007/s40273-024-01410-x

BibTeX
@article{Tomeny2024,
  author = {Tomeny, Ewan M and Hampton, Thomas and Tran, Phuong Bich and Rosu, Laura and Phiri, Mphatso D and Haigh, Kathryn A and Nidoi, Jasper and Wingfield, Tom and Worrall, Eve},
  title = {Rethinking Tuberculosis Morbidity Quantification: A Systematic Review and Critical Appraisal of TB Disability Weights in Cost-Effectiveness Analyses},
  journal = {PharmacoEconomics},
  year = {2024},
  doi = {10.1007/s40273-024-01410-x}
}
Kostenlos starten →